MERS-CoV spike protein: Targets for vaccines and therapeutics

Antiviral Research

Volumn 133, Issue , 2016, Pages 165-177

  Wang, Qihui ^a,b   Wong, Gary ^a,b,c   Lu, Guangwen ^d   Yan, Jinghua ^a,b,e   Gao, George F ^a,b,c,e,f,g  

^a INSTITUTE OF MICROBIOLOGY   (China)

^b SHENZHEN THIRD PEOPLE S HOSPITAL   (China)

^c INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^d SICHUAN UNIVERSITY   (China)

^e UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^f CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^g ZHEJIANG UNIVERSITY   (China)

Author keywords

Animal models; Coronavirus; MERS CoV; Spike protein; Therapeutics; Vaccines

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DNA VACCINE; NEUTRALIZING ANTIBODY; SUBUNIT VACCINE; VACCINIA VACCINE; VIRUS SPIKE PROTEIN; VIRUS VACCINE; ANTIVIRUS AGENT; CORONAVIRUS SPIKE GLYCOPROTEIN; VIRUS ANTIBODY; VIRUS LIKE PARTICLE VACCINE; VIRUS RECEPTOR;

DRUG EFFICACY; HUMAN; LIFE CYCLE STAGE; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; NONHUMAN; PHAGE DISPLAY; PRIMATE; PRIORITY JOURNAL; PROTEIN TARGETING; REPLICON; REVIEW; SCREENING; VACCINATION; VACCINIA VIRUS; VIRUS ENTRY; VIRUS MORPHOLOGY; VIRUS NEUTRALIZATION; ANIMAL; CHEMISTRY; CORONAVIRUS INFECTION; DRUG DEVELOPMENT; GENETICS; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; CORONAVIRUS INFECTIONS; DRUG DISCOVERY; HUMANS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; RECEPTORS, VIRUS; SPIKE GLYCOPROTEIN, CORONAVIRUS; STRUCTURE-ACTIVITY RELATIONSHIP; VACCINES, DNA; VACCINES, SUBUNIT; VACCINES, VIRUS-LIKE PARTICLE; VIRAL VACCINES; VIRUS INTERNALIZATION;

EID: 84982176821     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2016.07.015     Document Type: Review

References (151)

1. Adedeji, A.O., Sarafianos, S.G., Antiviral drugs specific for coronaviruses in preclinical development. Curr. Opin. Virol. 8 (2014), 45–53.
2. Agrawal, A.S., Garron, T., Tao, X.R., Peng, B.H., Wakamiya, M., Chan, T.S., Couch, R.B., Tseng, C.T.K., Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease. J. Virol. 89 (2015), 3659–3670.
3. Al-Tawfiq, J.A., Momattin, H., Dib, J., Memish, Z.A., Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int. J. Infect. Dis. 20 (2014), 42–46.
4. Alagaili, A.N., Briese, T., Mishra, N., Kapoor, V., Sameroff, S.C., Burbelo, P.D., de Wit, E., Munster, V.J., Hensley, L.E., Zalmout, I.S., Kapoor, A., Epstein, J.H., Karesh, W.B., Daszak, P., Mohammed, O.B., Lipkin, W.I., Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia. mBio, 5, 2014 e00884-14.
5. Almeida, J.D., Tyrrell, D.A., The morphology of three previously uncharacterized human respiratory viruses that grow in organ culture. J. Gen. Virol. 1 (1967), 175–178.
6. Azhar, E.I., El-Kafrawy, S.A., Farraj, S.A., Hassan, A.M., Al-Saeed, M.S., Hashem, A.M., Madani, T.A., Evidence for camel-to-human transmission of MERS coronavirus. N. Engl. J. Med. 370 (2014), 2499–2505.
7. Baez-Santos, Y.M., Mielech, A.M., Deng, X.F., Baker, S., Mesecar, A.D., Catalytic function and substrate specificity of the papain-like protease domain of nsp3 from the Middle East respiratory syndrome coronavirus. J. Virol. 88 (2014), 12511–12527.
8. Barouch, D.H., Yang, Z.Y., Kong, W.P., Korioth-Schmitz, B., Sumida, S.M., Truitt, D.M., Kishko, M.G., Arthur, J.C., Miura, A., Mascola, J.R., Letvin, N.L., Nabel, G.J., A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. J. Virol. 79 (2005), 8828–8834.
9. Belouzard, S., Millet, J.K., Licitra, B.N., Whittaker, G.R., Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses 4 (2012), 1011–1033.
10. Bermingham, A., Chand, M.A., Brown, C.S., Aarons, E., Tong, C., Langrish, C., Hoschler, K., Brown, K., Galiano, M., Myers, R., Pebody, R.G., Green, H.K., Boddington, N.L., Gopal, R., Price, N., Newsholme, W., Drosten, C., Fouchier, R.A., Zambon, M., Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. Euro. Surveill. 17 (2012), 20290–20294.
11. Blacklow, S.C., Lu, M., Kim, P.S., A trimeric subdomain of the simian immunodeficiency virus envelope glycoprotein. Biochemistry 34 (1995), 14955–14962.
12. Bossart, K.N., Geisbert, T.W., Feldmann, H., Zhu, Z., Feldmann, F., Geisbert, J.B., Yan, L., Feng, Y.R., Brining, D., Scott, D., Wang, Y., Dimitrov, A.S., Callison, J., Chan, Y.P., Hickey, A.C., Dimitrov, D.S., Broder, C.C., Rockx, B., A neutralizing human monoclonal antibody protects african green monkeys from hendra virus challenge. Sci. Transl. Med., 3, 2011, 105ra103.
13. Bossart, K.N., Zhu, Z., Middleton, D., Klippel, J., Crameri, G., Bingham, J., McEachern, J.A., Green, D., Hancock, T.J., Chan, Y.P., Hickey, A.C., Dimitrov, D.S., Wang, L.F., Broder, C.C., A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection. PLoS Pathog., 5, 2009, e1000642.
14. Bruggemann, M., Osborn, M.J., Ma, B., Hayre, J., Avis, S., Lundstrom, B., Buelow, R., Human antibody production in transgenic animals. Arch. Immunol. Ther. Exp. Warsz. 63 (2015), 101–108.
15. Carmichael, L.E., Canine viral vaccines at a turning point - a personal perspective. Adv. Veter Med. Ap 41 (1999), 289–307.
16. Carter, P.J., Potent antibody therapeutics by design. Nat. Rev. Immunol. 6 (2006), 343–357.
17. Catanzaro, A.T., Roederer, M., Koup, R.A., Bailer, R.T., Enama, M.E., Nason, M.C., Martin, J.E., Rucker, S., Andrews, C.A., Gomez, P.L., Mascola, J.R., Nabel, G.J., Graham, B.S., Team, V.R.C.S., Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine 25 (2007), 4085–4092.
18. Cavanagh, D., Coronavirus avian infectious bronchitis virus. Vet. Res. 38 (2007), 281–297.
19. Chan, J.F., Chan, K.H., Kao, R.Y., To, K.K., Zheng, B.J., Li, C.P., Li, P.T., Dai, J., Mok, F.K., Chen, H., Hayden, F.G., Yuen, K.Y., Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J. Infect. 67 (2013), 606–616.
20. Chan, J.F., Yao, Y., Yeung, M.L., Deng, W., Bao, L., Jia, L., Li, F., Xiao, C., Gao, H., Yu, P., Cai, J.P., Chu, H., Zhou, J., Chen, H., Qin, C., Yuen, K.Y., Treatment with lopinavir/ritonavir or interferon-beta1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J. Infect. Dis. 212 (2015), 1904–1913.
21. Channappanavar, R., Lu, L., Xia, S., Du, L., Meyerholz, D.K., Perlman, S., Jiang, S., Protective effect of intranasal regimens containing peptidic Middle East respiratory syndrome coronavirus fusion inhibitor against MERS-CoV infection. J. Infect. Dis. 212 (2015), 1894–1903.
22. Cheng, K.W., Cheng, S.C., Chen, W.Y., Lin, M.H., Chuang, S.J., Cheng, I.H., Sun, C.Y., Chou, C.Y., Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus. Antivir. Res. 115 (2015), 9–16.
23. Chu, L.H., Chan, S.H., Tsai, S.N., Wang, Y., Cheng, C.H., Wong, K.B., Waye, M.M., Ngai, S.M., Fusion core structure of the severe acute respiratory syndrome coronavirus (SARS-CoV): in search of potent SARS-CoV entry inhibitors. J. Cell Biochem. 104 (2008), 2335–2347.
24. Cotten, M., Lam, T.T., Watson, S.J., Palser, A.L., Petrova, V., Grant, P., Pybus, O.G., Rambaut, A., Guan, Y., Pillay, D., Kellam, P., Nastouli, E., Full-genome deep sequencing and phylogenetic analysis of novel human betacoronavirus. Emerg. Infect. Dis. 19 (2013), 736–742B.
25. De Gregorio, E., Caproni, E., Ulmer, J.B., Vaccine adjuvants: mode of action. Front. Immunol. 4 (2013), 214–219.
26. de Groot, R.J., Baker, S.C., Baric, R.S., Brown, C.S., Drosten, C., Enjuanes, L., Fouchier, R.A.M., Galiano, M., Gorbalenya, A.E., Memish, Z.A., Perlman, S., Poon, L.L.M., Snijder, E.J., Stephens, G.M., Woo, P.C.Y., Zaki, A.M., Zambon, M., Ziebuhr, J., Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J. Virol. 87 (2013), 7790–7792.
27. de Wilde, A.H., Jochmans, D., Posthuma, C.C., Zevenhoven-Dobbe, J.C., van Nieuwkoop, S., Bestebroer, T.M., van den Hoogen, B.G., Neyts, J., Snijder, E.J., Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob. Agents Ch. 58 (2014), 4875–4884.
28. de Wit, E., Rasmussen, A.L., Falzarano, D., Bushmaker, T., Feldmann, F., Brining, D.L., Fischer, E.R., Martellaro, C., Okumura, A., Chang, J., Scott, D., Benecke, A.G., Katze, M.G., Feldmann, H., Munster, V.J., Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 16598–16603.
29. Debnath, A.K., Radigan, L., Jiang, S., Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1. J. Med. Chem. 42 (1999), 3203–3209.
30. DiGiandomenico, A., Sellman, B.R., Antibacterial monoclonal antibodies: the next generation?. Curr. Opin. Microbiol. 27 (2015), 78–85.
31. Dimitrov, D.S., Therapeutic proteins. Methods Mol. Biol. 899 (2012), 1–26.
32. Du, L., Kou, Z., Ma, C., Tao, X., Wang, L., Zhao, G., Chen, Y., Yu, F., Tseng, C.T., Zhou, Y., Jiang, S., A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. PLoS One, 8, 2013, e81587.
33. Du, L.Y., He, Y.X., Zhou, Y.S., Liu, S.W., Zheng, B.J., Jiang, S.B., The spike protein of SARS-CoV - a target for vaccine and therapeutic development. Nat. Rev. Microbiol. 7 (2009), 226–236.
34. Du, L.Y., Zhao, G.Y., Kou, Z.H., Ma, C.Q., Sun, S.H., Poon, V.K.M., Lu, L., Wang, L.L., Debnath, A.K., Zheng, B.J., Zhou, Y.S., Jiang, S.B., Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. J. Virol. 87 (2013), 9939–9942.
35. Earp, L.J., Delos, S.E., Park, H.E., White, J.M., The many mechanisms of viral membrane fusion proteins. Curr. Top. Microbiol. Immunol. 285 (2005), 25–66.
36. Economides, A.N., Frendewey, D., Yang, P., Dominguez, M.G., Dore, A.T., Lobov, I.B., Persaud, T., Rojas, J., McClain, J., Lengyel, P., Droguett, G., Chernomorsky, R., Stevens, S., Auerbach, W., Dechiara, T.M., Pouyemirou, W., Cruz, J.M. Jr., Feeley, K., Mellis, I.A., Yasenchack, J., Hatsell, S.J., Xie, L., Latres, E., Huang, L., Zhang, Y., Pefanis, E., Skokos, D., Deckelbaum, R.A., Croll, S.D., Davis, S., Valenzuela, D.M., Gale, N.W., Murphy, A.J., Yancopoulos, G.D., Conditionals by inversion provide a universal method for the generation of conditional alleles. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), E3179–E3188.
37. Falsey, A.R., McCann, R.M., Hall, W.J., Criddle, M.M., Formica, M.A., Wycoff, D., Kolassa, J.E., The 'common cold' in frail older persons: impact of rhinovirus and coronavirus in a senior daycare center. J. Am. Geriatr. Soc. 45 (1997), 706–711.
38. Falzarano, D., de Wit, E., Feldmann, F., Rasmussen, A.L., Okumura, A., Peng, X., Thomas, M.J., van Doremalen, N., Haddock, E., Nagy, L., LaCasse, R., Liu, T., Zhu, J., McLellan, J.S., Scott, D.P., Katze, M.G., Feldmann, H., Munster, V.J., Infection with MERS-CoV causes lethal pneumonia in the common marmoset. PLoS Pathog., 10, 2014, e1004250.
39. Falzarano, D., de Wit, E., Martellaro, C., Callison, J., Munster, V.J., Feldmann, H., Inhibition of novel beta coronavirus replication by a combination of interferon-alpha2b and ribavirin. Sci. Rep. 3 (2013), 1686–1691.
40. Falzarano, D., de Wit, E., Rasmussen, A.L., Feldmann, F., Okumura, A., Scott, D.P., Brining, D., Bushmaker, T., Martellaro, C., Baseler, L., Benecke, A.G., Katze, M.G., Munster, V.J., Feldmann, H., Treatment with interferon-[alpha]2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat. Med. 19 (2013), 1313–1317.
41. Ferraro, B., Morrow, M.P., Hutnick, N.A., Shin, T.H., Lucke, C.E., Weiner, D.B., Clinical applications of DNA vaccines: current progress. Clin. Infect. Dis. 53 (2011), 296–302.
42. Gao, G.F., Peptide inhibitors targeting virus-cell fusion in class I enveloped viruses. Torrence, P.F., (eds.) Combating the Threat of Pandemic Influenza: Drug Discovery Approaches, 2007, John Wiley & Sons Inc, Hoboken, NJ, 226–246.
43. Gao, J., Lu, G., Qi, J., Li, Y., Wu, Y., Deng, Y., Geng, H., Li, H., Wang, Q., Xiao, H., Tan, W., Yan, J., Gao, G.F., Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus. J. Virol. 87 (2013), 13134–13140.
44. Gilbert, S.C., Clinical development of modified vaccinia virus Ankara vaccines. Vaccine 31 (2013), 4241–4246.
45. Haagmans, B.L., van den Brand, J.M.A., Raj, V.S., Volz, A., Wohlsein, P., Smits, S.L., Schipper, D., Bestebroer, T.M., Okba, N., Fux, R., Bensaid, A., Solanes Foz, D., Kuiken, T., Baumgärtner, W., Segalés, J., Sutter, G., Osterhaus, A.D.M.E., An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels. Science 351 (2016), 77–81.
46. Hamre, D., Procknow, J.J., A new virus isolated from the human respiratory tract. Proc. Soc. Exp. Biol. Med. 121 (1966), 190–193.
47. Harrison, S.C., Viral membrane fusion. Virology 479–480 (2015), 498–507.
48. Hasan, M.M., Akter, R., Ullah, M.S., Abedin, M.J., Ullah, G.M., Hossain, M.Z., A computational approach for predicting role of human microRNAs in MERS-CoV genome. Adv. Bioinforma. 2014 (2014), 967946–967953.
49. Heikkinen, T., Jarvinen, A., The common cold. Lancet 361 (2003), 51–59.
50. Hemida, M.G., Chu, D.K., Poon, L.L., Perera, R.A., Alhammadi, M.A., Ng, H.Y., Siu, L.Y., Guan, Y., Alnaeem, A., Peiris, M., MERS coronavirus in dromedary camel herd, Saudi Arabia. Emerg. Infect. Dis. 20 (2014), 1231–1234.
51. Hendley, J.O., Fishburne, H.B., Gwaltney, J.M. Jr., Coronavirus infections in working adults. Eight-year study with 229 E and OC 43. Am. Rev. Respir. Dis. 105 (1972), 805–811.
52. Hick, P.M., Read, A.J., Lugton, I., Busfield, F., Dawood, K.E., Gabor, L., Hornitzky, M., Kirkland, P.D., Coronavirus infection in intensively managed cattle with respiratory disease. Aust. Vet. J. 90 (2012), 381–386.
53. Houser, K.V., Gretebeck, L., Ying, T., Wang, Y., Vogel, L., Lamirande, E.W., Bock, K.W., Moore, I.N., Dimitrov, D.S., Subbarao, K., Prophylaxis With a Middle East Respiratory Syndrome Coronavirus (MERS-CoV) -Specific Human Monoclonal Antibody Protects Rabbits From MERS-CoV Infection. J. Infect. Dis. 213 (2016), 1557–1561.
54. Jiang, L.W., Wang, N.S., Zuo, T., Shi, X.L., Poon, K.M.V., Wu, Y.K., Gao, F., Li, D.Y., Wang, R.K., Guo, J.Y., Fu, L.L., Yuen, K.Y., Zheng, B.J., Wang, X.Q., Zhang, L.Q., Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. Sci. Transl. Med., 6, 2014 234ra59.
55. Jiang, S., Lin, K., Effect of amino acid replacements, additions and deletions on the antiviral activity of a peptide derived from the HIV-1 GP41 sequence. Pept. Res. 8 (1995), 345–348.
56. Jiang, S., Lin, K., Strick, N., Neurath, A.R., HIV-1 inhibition by a peptide. Nature, 365, 1993, 113.
57. Keum, Y.S., Jeong, Y.J., Development of chemical inhibitors of the SARS coronavirus: viral helicase as a potential target. Biochem. Pharmacol. 84 (2012), 1351–1358.
58. Khalafalla, A.I., Lu, X., Al-Mubarak, A.I., Dalab, A.H., Al-Busadah, K.A., Erdman, D.D., MERS-CoV in upper respiratory tract and lungs of dromedary camels, Saudi Arabia, 2013-2014. Emerg. Infect. Dis. 21 (2015), 1153–1158.
59. Kielian, M., Rey, F.A., Virus membrane-fusion proteins: more than one way to make a hairpin. Nat. Rev. Microbiol. 4 (2006), 67–76.
60. Kilianski, A., Mielech, A.M., Deng, X.F., Baker, S.C., Assessing activity and inhibition of Middle East respiratory syndrome coronavirus papain-like and 3C-like proteases using luciferase-based biosensors. J. Virol. 87 (2013), 11955–11962.
61. Kirchdoerfer, R.N., Cottrell, C.A., Wang, N., Pallesen, J., Yassine, H.M., Turner, H.L., Corbett, K.S., Graham, B.S., McLellan, J.S., Ward, A.B., Pre-fusion structure of a human coronavirus spike protein. Nature 531 (2016), 118–121.
62. Kumar, V., Jung, Y.S., Liang, P.H., Anti-SARS coronavirus agents: a patent review (2008-present). Expert Opin. Ther. Pat. 23 (2013), 1337–1348.
63. Li, F., Li, W., Farzan, M., Harrison, S.C., Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 309 (2005), 1864–1868.
64. Li, L., Qiu, J., Lu, L., An, S., Qiao, P., Jiang, S., Liu, S., 3-Hydroxyphthalic anhydride-modified human serum albumin as a microbicide candidate inhibits HIV infection by blocking viral entry. J. Antimicrob. Chemother. 68 (2013), 573–576.
65. Li, W., Joshi, M.D., Singhania, S., Ramsey, K.H., Murthy, A.K., Peptide vaccine: progress and challenges. Vaccines (Basel) 2 (2014), 515–536.
66. Li, Y., Wan, Y.H., Liu, P.P., Zhao, J.C., Lu, G.W., Qi, J.X., Wang, Q.H., Lu, X.C., Wu, Y., Liu, W.J., Zhang, B.C., Yuen, K.Y., Perlman, S., Gao, G.F., Yan, J.H., A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein. Cell Res. 25 (2015), 1237–1249.
67. Liang, P.H., Characterization and inhibition of SARS-coronavirus main protease. Curr. Top. Med. Chem. 6 (2006), 361–376.
68. Lingwood, D., McTamney, P.M., Yassine, H.M., Whittle, J.R., Guo, X., Boyington, J.C., Wei, C.J., Nabel, G.J., Structural and genetic basis for development of broadly neutralizing influenza antibodies. Nature 489 (2012), 566–570.
69. Lombardi, S., Massi, C., Indino, E., La Rosa, C., Mazzetti, P., Falcone, M.L., Rovero, P., Fissi, A., Pieroni, O., Bandecchi, P., Esposito, F., Tozzini, F., Bendinelli, M., Garzelli, C., Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides. Virology 220 (1996), 274–284.
70. Lu, G., Hu, Y., Wang, Q., Qi, J., Gao, F., Li, Y., Zhang, Y., Zhang, W., Yuan, Y., Bao, J., Zhang, B., Shi, Y., Yan, J., Gao, G.F., Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 500 (2013), 227–231.
71. Lu, G., Wang, Q., Gao, G.F., Bat-to-human: spike features determining 'host jump' of coronaviruses SARS-CoV, MERS-CoV, and beyond. Trends Microbiol. 23 (2015), 468–478.
72. Lu, G.W., Qi, J.X., Chen, Z.J., Xu, X., Gao, F., Lin, D.Z., Qian, W.K., Liu, H., Jiang, H.L., Yan, J.H., Gao, G.F., Enterovirus 71 and coxsackievirus A16 3C proteases: binding to rupintrivir and their substrates and anti-hand, foot, and mouth disease virus drug design. J. Virol. 85 (2011), 10319–10331.
73. Lu, L., Liu, Q., Zhu, Y., Chan, K.H., Qin, L., Li, Y., Wang, Q., Chan, J.F., Du, L., Yu, F., Ma, C., Ye, S., Yuen, K.Y., Zhang, R., Jiang, S., Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat. Commun., 5, 2014, 3067.
74. Lu, L., Yang, X., Li, Y., Jiang, S., Chemically modified bovine beta-lactoglobulin inhibits human papillomavirus infection. Microbes Infect. 15 (2013), 506–510.
75. Lundstrom, K., Alphavirus-based vaccines. Viruses 6 (2014), 2392–2415.
76. Ma, C.Q., Li, Y., Wang, L.L., Zhao, G.Y., Tao, X.R., Tseng, C.T.K., Zhou, Y.S., Du, L.Y., Jiang, S.B., Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: implication for designing novel mucosal MERS vaccines. Vaccine 32 (2014), 2100–2108.
77. Ma, C.Q., Wang, L.L., Tao, X.R., Zhang, N.R., Yang, Y., Tseng, C.T.K., Li, F., Zhou, Y.S., Jiang, S.B., Du, L.Y., Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments-The importance of immunofocusing in subunit vaccine design. Vaccine 32 (2014), 6170–6176.
78. Mascola, J.R., Haynes, B.F., HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol. Rev. 254 (2013), 225–244.
79. McIntosh, K., Chao, R.K., Krause, H.E., Wasil, R., Mocega, H.E., Mufson, M.A., Coronavirus infection in acute lower respiratory tract disease of infants. J. Infect. Dis. 130 (1974), 502–507.
80. McIntosh, K., Dees, J.H., Becker, W.B., Kapikian, A.Z., Chanock, R.M., Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease. Proc. Natl. Acad. Sci. U. S. A. 57 (1967), 933–940.
81. Melikyan, G.B., Common principles and intermediates of viral protein-mediated fusion: the HIV-1 paradigm. Retrovirology, 5, 2008, 111.
82. Memish, Z.A., Cotten, M., Meyer, B., Watson, S.J., Alsahafi, A.J., Al Rabeeah, A.A., Corman, V.M., Sieberg, A., Makhdoom, H.Q., Assiri, A., Al Masri, M., Aldabbagh, S., Bosch, B.J., Beer, M., Muller, M.A., Kellam, P., Drosten, C., Human infection with MERS coronavirus after exposure to infected camels, Saudi Arabia, 2013. Emerg. Infect. Dis. 20 (2014), 1012–1015.
83. Millet, J.K., Whittaker, G.R., Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 15214–15219.
84. Millet, J.K., Whittaker, G.R., Host cell proteases: critical determinants of coronavirus tropism and pathogenesis. Virus Res. 202 (2015), 120–134.
85. Mou, H., Raj, V.S., van Kuppeveld, F.J.M., Rottier, P.J.M., Haagmans, B.L., Bosch, B.J., The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies. J. Virol. 87 (2013), 9379–9383.
86. Munster, V.J., de Wit, E., Feldmann, H., Pneumonia from human coronavirus in a macaque model. N. Engl. J. Med. 368 (2013), 1560–1562.
87. Murphy, A.J., Macdonald, L.E., Stevens, S., Karow, M., Dore, A.T., Pobursky, K., Huang, T.T., Poueymirou, W.T., Esau, L., Meola, M., Mikulka, W., Krueger, P., Fairhurst, J., Valenzuela, D.M., Papadopoulos, N., Yancopoulos, G.D., Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 5153–5158.
88. Muthumani, K., Falzarano, D., Reuschel, E.L., Tingey, C., Flingai, S., Villarreal, D.O., Wise, M., Patel, A., Izmirly, A., Aljuaid, A., Seliga, A.M., Soule, G., Morrow, M., Kraynyak, K.A., Khan, A.S., Scott, D.P., Feldmann, F., LaCasse, R., Meade-White, K., Okumura, A., Ugen, K.E., Sardesai, N.Y., Kim, J.J., Kobinger, G., Feldmann, H., Weiner, D.B., A synthetic consensus anti–spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Sci. Transl. Med., 7, 2015 301ra132.
89. Narayanan, K., Huang, C., Makino, S., SARS coronavirus accessory proteins. Virus Res. 133 (2008), 113–121.
90. Naz, R.K., Dabir, P., Peptide vaccines against cancer, infectious diseases, and conception. Front. Biosci. 12 (2007), 1833–1844.
91. Niemeyer, D., Zillinger, T., Muth, D., Zielecki, F., Horvath, G., Suliman, T., Barchet, W., Weber, F., Drosten, C., Muller, M.A., Middle East respiratory syndrome coronavirus accessory protein 4a is a Type I interferon antagonist. J. Virol. 87 (2013), 12489–12495.
92. Nokso-Koivisto, J., Pitkaranta, A., Blomqvist, S., Kilpi, T., Hovi, T., Respiratory coronavirus infections in children younger than two years of age. Pediatr. Infect. Dis. J. 19 (2000), 164–166.
93. Nur, S.M., Hasan, M.A., Amin, M.A., Hossain, M., Sharmin, T., Design of potential RNAi (miRNA and siRNA) molecules for Middle East respiratory syndrome coronavirus (MERS-CoV) gene silencing by computational method. Interdiscip. Sci. 7 (2014), 257–265.
94. Olsen, C.W., A review of feline infectious peritonitis virus: molecular biology, immunopathogenesis, clinical aspects, and vaccination. Vet. Microbiol. 36 (1993), 1–37.
95. Papaneri, A.B., Johnson, R.F., Wada, J., Bollinger, L., Jahrling, P.B., Kuhn, J.H., Middle East respiratory syndrome: obstacles and prospects for vaccine development. Expert Rev. Vaccines 14 (2015), 949–962.
96. Pascal, K.E., Coleman, C.M., Mujica, A.O., Kamat, V., Badithe, A., Fairhurst, J., Hunt, C., Strein, J., Berrebi, A., Sisk, J.M., Matthews, K.L., Babb, R., Chen, G., Lai, K.M.V., Huang, T.T., Olson, W., Yancopoulos, G.D., Stahl, N., Frieman, M.B., Kyratsous, C.A., Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 8738–8743.
97. Pene, F., Merlat, A., Vabret, A., Rozenberg, F., Buzyn, A., Dreyfus, F., Cariou, A., Freymuth, F., Lebon, P., Coronavirus 229E-related pneumonia in immunocompromised patients. Clin. Infect. Dis. 37 (2003), 929–932.
98. Podda, A., Del Giudice, G., MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev. vaccines 2 (2003), 197–203.
99. Qiu, X., Wong, G., Audet, J., Bello, A., Fernando, L., Alimonti, J.B., Fausther-Bovendo, H., Wei, H., Aviles, J., Hiatt, E., Johnson, A., Morton, J., Swope, K., Bohorov, O., Bohorova, N., Goodman, C., Kim, D., Pauly, M.H., Velasco, J., Pettitt, J., Olinger, G.G., Whaley, K., Xu, B., Strong, J.E., Zeitlin, L., Kobinger, G.P., Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514 (2014), 47–53.
100. Raj, V.S., Mou, H., Smits, S.L., Dekkers, D.H.W., Muller, M.A., Dijkman, R., Muth, D., Demmers, J.A.A., Zaki, A., Fouchier, R.A.M., Thiel, V., Drosten, C., Rottier, P.J.M., Osterhaus, A.D.M.E., Bosch, B.J., Haagmans, B.L., Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495 (2013), 251–254.
101. Ramajayam, R., Tan, K.P., Liang, P.H., Recent development of 3C and 3CL protease inhibitors for anti-coronavirus and anti-picornavirus drug discovery. Biochem. Soc. Trans. 39 (2011), 1371–1375.
102. Redding, L., Weiner, D.B., DNA vaccines in veterinary use. Expert Rev. Vaccines 8 (2009), 1251–1276.
103. Saif, L.J., Coronavirus immunogens. Vet. Microbiol. 37 (1993), 285–297.
104. Schmidt, A., Wolff, M.H., Weber, O.F., Coronaviruses with Special Emphasis on First Insights Concerning SARS. 2005, Birkhäuser Boston, Inc.
105. Shadman, K.A., Wald, E.R., A review of palivizumab and emerging therapies for respiratory syncytial virus. Expert Opin. Biol. Ther. 11 (2011), 1455–1467.
106. Simmons, G., Zmora, P., Gierer, S., Heurich, A., Pöhlmann, S., Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research. Antivir. Res. 100 (2013), 605–614.
107. Slovin, S.F., Kehoe, M., Durso, R., Fernandez, C., Olson, W., Gao, J.P., Israel, R., Scher, H.I., Morris, S., A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer. Vaccine 31 (2013), 943–949.
108. Song, F., Fux, R., Provacia, L.B., Volz, A., Eickmann, M., Becker, S., Osterhaus, A.D.M.E., Haagmans, B.L., Sutter, G., Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies. J. Virol. 87 (2013), 11950–11954.
109. Stockman, L.J., Bellamy, R., Garner, P., SARS: systematic review of treatment effects. PLoS Med., 3, 2006, e343.
110. Su, S., Wong, G., Liu, Y., Gao, G.F., Li, S., Bi, Y., MERS in South Korea and China: a potential outbreak threat?. Lancet 385 (2015), 2349–2350.
111. Tang, X.C., Agnihothram, S.S., Jiao, Y.J., Stanhope, J., Graham, R.L., Peterson, E.C., Avnir, Y., Tallarico, A.S., Sheehan, J., Zhu, Q., Baric, R.S., Marasco, W.A., Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), E2018–E2026.
112. Tao, X., Garron, T., Agrawal, A.S., Algaissi, A., Peng, B.H., Wakamiya, M., Chan, T.S., Lu, L., Du, L., Jiang, S., Couch, R.B., Tseng, C.T., Characterization and demonstration of the value of a lethal mouse model of Middle East respiratory syndrome coronavirus infection and disease. J. Virol. 90 (2015), 57–67.
113. Tyrrell, D.A., Bynoe, M.L., Cultivation of a novel Type of common-cold virus in organ cultures. Br. Med. J. 1 (1965), 1467–1470.
114. Ura, T., Okuda, K., Shimada, M., Developments in viral vector-based vaccines. Vaccines (Basel) 2 (2014), 624–641.
115. Vabret, A., Mourez, T., Gouarin, S., Petitjean, J., Freymuth, F., An outbreak of coronavirus OC43 respiratory infection in Normandy, France. Clin. Infect. Dis. 36 (2003), 985–989.
116. Valenzuela, D.M., Murphy, A.J., Frendewey, D., Gale, N.W., Economides, A.N., Auerbach, W., Poueymirou, W.T., Adams, N.C., Rojas, J., Yasenchak, J., Chernomorsky, R., Boucher, M., Elsasser, A.L., Esau, L., Zheng, J., Griffiths, J.A., Wang, X., Su, H., Xue, Y., Dominguez, M.G., Noguera, I., Torres, R., Macdonald, L.E., Stewart, A.F., DeChiara, T.M., Yancopoulos, G.D., High-throughput engineering of the mouse genome coupled with high-resolution expression analysis. Nat. Biotechnol. 21 (2003), 652–659.
117. van Boheemen, S., de Graaf, M., Lauber, C., Bestebroer, T.M., Raj, V.S., Zaki, A.M., Osterhaus, A.D., Haagmans, B.L., Gorbalenya, A.E., Snijder, E.J., Fouchier, R.A., Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. mBio, 3, 2012 e00473-12.
118. van der Hoek, L., Pyrc, K., Jebbink, M.F., Vermeulen-Oost, W., Berkhout, R.J., Wolthers, K.C., Wertheim-van Dillen, P.M., Kaandorp, J., Spaargaren, J., Berkhout, B., Identification of a new human coronavirus. Nat. Med. 10 (2004), 368–373.
119. van Doremalen, N., Munster, V.J., Animal models of Middle East respiratory syndrome coronavirus infection. Antivir. Res. 122 (2015), 28–38.
120. Volz, A., Kupke, A., Song, F., Jany, S., Fux, R., Shams-Eldin, H., Schmidt, J., Becker, C., Eickmann, M., Becker, S., Sutter, G., Protective efficacy of recombinant modified vaccinia virus Ankara delivering Middle East respiratory syndrome coronavirus spike glycoprotein. J. Virol. 89 (2015), 8651–8656.
121. Walls, A.C., Tortorici, M.A., Bosch, B.J., Frenz, B., Rottier, P.J.M., DiMaio, F., Rey, F.A., Veesler, D., Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer. Nature 531 (2016), 114–117.
122. Wang, E., Sun, X., Qian, Y., Zhao, L., Tien, P., Gao, G.F., Both heptad repeats of human respiratory syncytial virus fusion protein are potent inhibitors of viral fusion. Biochem. Bioph Res. Co. 302 (2003), 469–475.
123. Wang, H., Qi, Z., Guo, A., Mao, Q., Lu, H., An, X., Xia, C., Li, X., Debnath, A.K., Wu, S., Liu, S., Jiang, S., ADS-J1 inhibits human immunodeficiency virus type 1 entry by interacting with the gp41 pocket region and blocking fusion-active gp41 core formation. Antimicrob. Agents Ch. 53 (2009), 4987–4998.
124. Wang, L., Shi, W., Joyce, M.G., Modjarrad, K., Zhang, Y., Leung, K., Lees, C.R., Zhou, T., Yassine, H.M., Kanekiyo, M., Yang, Z.Y., Chen, X., Becker, M.M., Freeman, M., Vogel, L., Johnson, J.C., Olinger, G., Todd, J.P., Bagci, U., Solomon, J., Mollura, D.J., Hensley, L., Jahrling, P., Denison, M.R., Rao, S.S., Subbarao, K., Kwong, P.D., Mascola, J.R., Kong, W.P., Graham, B.S., Evaluation of candidate vaccine approaches for MERS-CoV. Nat. Commun., 6, 2015, 7712.
125. Wang, N., Shi, X., Jiang, L., Zhang, S., Wang, D., Tong, P., Guo, D., Fu, L., Cui, Y., Liu, X., Arledge, K.C., Chen, Y.H., Zhang, L., Wang, X., Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res. 23 (2013), 986–993.
126. Wang, Q., Qi, J., Yuan, Y., Xuan, Y., Han, P., Wan, Y., Ji, W., Li, Y., Wu, Y., Wang, J., Iwamoto, A., Woo, P.C., Yuen, K.Y., Yan, J., Lu, G., Gao, G.F., Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26. Cell Host Microbe 16 (2014), 328–337.
127. Watanabe, S., Takada, A., Watanabe, T., Ito, H., Kida, H., Kawaoka, Y., Functional importance of the coiled-coil of the Ebola virus glycoprotein. J. Virol. 74 (2000), 10194–10201.
128. Wecker, M., Gilbert, P., Russell, N., Hural, J., Allen, M., Pensiero, M., Chulay, J., Chiu, Y.L., Karim, S.S.A., Burke, D.S., Team, H.P., Network, N.H.V.T., Phase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine in healthy HIV-1-uninfected adults. Clin. Vaccine Immunol. 19 (2012), 1651–1660.
129. Welter, M.W., Horstman, M.P., Welter, C.J., Welter, L.M., An overview of successful TGEV vaccination strategies and discussion on the interrelationship between TGEV and PRCV. Coronaviruses 342 (1993), 463–468.
130. White, J.M., Delos, S.E., Brecher, M., Schornberg, K., Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme (vol. 43, pg 189, 2008). Crit. Rev. Biochem. Mol. 43 (2008), 287–288.
131. WHO, Cumulative Number of Reported Probable Cases of Severe Acute Respiratory Syndrome (SARS). 2004 http://www.who.int/csr/sars/country/en/.
132. WHO, Middle East Respiratory Syndrome Coronavirus (MERS-cov) – Update. 2016 http://www.who.int/csr/don/7-january-2016-mers-oman/en/.
133. Wong, G., Liu, W., Liu, Y., Zhou, B., Bi, Y., Gao, G.F., MERS, SARS, and Ebola: The role of super-spreaders in infectious disease. Cell Host Microbe 18 (2015), 398–401.
134. Woo, P.C., Lau, S.K., Chu, C.M., Chan, K.H., Tsoi, H.W., Huang, Y., Wong, B.H., Poon, R.W., Cai, J.J., Luk, W.K., Poon, L.L., Wong, S.S., Guan, Y., Peiris, J.S., Yuen, K.Y., Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. J. Virol. 79 (2005), 884–895.
135. Xia, S., Liu, Q., Wang, Q., Sun, Z., Su, S., Du, L., Ying, T., Lu, L., Jiang, S., Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein. Virus Res. 194 (2014), 200–210.
136. Yang, H., Yang, M., Ding, Y., Liu, Y., Lou, Z., Zhou, Z., Sun, L., Mo, L., Ye, S., Pang, H., Gao, G.F., Anand, K., Bartlam, M., Hilgenfeld, R., Rao, Z., The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 13190–13195.
137. Yang, H.T., Bartlam, M., Rao, Z.H., Drug design targeting the main protease, the Achilles' heel of coronaviruses. Curr. Pharm. Des. 12 (2006), 4573–4590.
138. Yang, X., Chen, X., Bian, G., Tu, J., Xing, Y., Wang, Y., Chen, Z., Proteolytic processing, deubiquitinase and interferon antagonist activities of Middle East respiratory syndrome coronavirus papain-like protease. J. Gen. Virol. 95 (2014), 614–626.
139. Yang, Y., Liu, C., Du, L., Jiang, S., Shi, Z., Baric, R.S., Li, F., Two mutations were critical for bat-to-human transmission of Middle East respiratory syndrome coronavirus. J. Virol. 89 (2015), 9119–9123.
140. Yang, Y., Zhang, L., Geng, H., Deng, Y., Huang, B., Guo, Y., Zhao, Z., Tan, W., The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists. Protein & Cell 4 (2013), 951–961.
141. Yao, Y., Bao, L., Deng, W., Xu, L., Li, F., Lv, Q., Yu, P., Chen, T., Xu, Y., Zhu, H., Yuan, J., Gu, S., Wei, Q., Chen, H., Yuen, K.Y., Qin, C., An animal model of MERS produced by infection of rhesus macaques with MERS coronavirus. J. Infect. Dis. 209 (2014), 236–242.
142. Ying, T.L., Prabakaran, P., Du, L.Y., Shi, W., Feng, Y., Wang, Y.P., Wang, L.S., Li, W., Jiang, S.B., Dimitrov, D.S., Zhou, T.Q., Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody. Nat. Commun., 6, 2015, 8223.
143. Yu, M., Wang, E., Liu, Y., Cao, D., Jin, N., Zhang, C.W., Bartlam, M., Rao, Z., Tien, P., Gao, G.F., Six-helix bundle assembly and characterization of heptad repeat regions from the F protein of Newcastle disease virus. J. Gen. Virol. 83 (2002), 623–629.
144. Yu, X.J., Zhang, S.Y., Jiang, L.W., Cui, Y., Li, D.X., Wang, D.L., Wang, N.S., Fu, L.L., Shi, X.L., Li, Z.Q., Zhang, L.Q., Wang, X.Q., Structural basis for the neutralization of MERS-CoV by a human monoclonal antibody MERS-27. Sci. Rep. 5 (2015), 13133–13143.
145. Zaki, A.M., van Boheemen, S., Bestebroer, T.M., Osterhaus, A.D., Fouchier, R.A., Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 367 (2012), 1814–1820.
146. Zhang, N., Channappanavar, R., Ma, C., Wang, L., Tang, J., Garron, T., Tao, X., Tasneem, S., Lu, L., Tseng, C.T., Zhou, Y., Perlman, S., Jiang, S., Du, L., Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus. Cell Mol. Immunol. 13 (2016), 180–190.
147. Zhang, N., Jiang, S., Du, L., Current advancements and potential strategies in the development of MERS-CoV vaccines. Expert Rev. Vaccines 13 (2014), 761–774.
148. Zhao, G.Y., Du, L.Y., Ma, C.Q., Li, Y., Li, L., Poon, V.K.M., Wang, L.L., Yu, F., Zheng, B.J., Jiang, S.B., Zhou, Y.S., A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV. Virol. J., 10, 2013, 266.
149. Zhao, G.Y., Jiang, Y.T., Qiu, H.J., Gao, T.T., Zeng, Y., Guo, Y., Yu, H., Li, J.F., Kou, Z.H., Du, L.Y., Tan, W.J., Jiang, S.B., Sun, S.H., Zhou, Y.S., Multi-organ damage in human dipeptidyl peptidase 4 transgenic mice infected with Middle East respiratory syndrome-coronavirus. PLoS One, 10, 2015, e0145561.
150. Zhao, J., Li, K., Wohlford-Lenane, C., Agnihothram, S.S., Fett, C., Zhao, J., Gale, M.J. Jr., Baric, R.S., Enjuanes, L., Gallagher, T., McCray, P.B. Jr., Perlman, S., Rapid generation of a mouse model for Middle East respiratory syndrome. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 4970–4975.
151. Zhu, Z., Dimitrov, A.S., Bossart, K.N., Crameri, G., Bishop, K.A., Choudhry, V., Mungall, B.A., Feng, Y.R., Choudhary, A., Zhang, M.Y., Feng, Y., Wang, L.F., Xiao, X., Eaton, B.T., Broder, C.C., Dimitrov, D.S., Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies. J. Virol. 80 (2006), 891–899.